[NESTLE] QoQ Cumulative Quarter Result on 30-Jun-2015 [#2]

Stock
[NESTLE] NESTLE (M) BHD
Announcement Date
12-Aug-2015
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2015
Quarter
30-Jun-2015 [#2]
Profit Trend
QoQ- 65.95%
YoY- 3.24%
Quarter Report
Latest QR
Upcoming QR
NESTLE's Result
NESTLE's Financial Summary
View:
Show?
Cumulative Result
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Revenue 1,313,462 4,837,957 3,639,015 2,420,630 1,277,729 4,808,933 3,700,171 -49.83%
PBT 275,858 727,711 609,033 403,808 244,252 701,187 583,690 -39.29%
Tax -55,181 -136,978 -118,090 -92,027 -56,374 -150,803 -131,610 -43.95%
NP 220,677 590,733 490,943 311,781 187,878 550,384 452,080 -37.97%
-
NP to SH 220,677 590,733 490,943 311,781 187,878 550,384 452,080 -37.97%
-
Tax Rate 20.00% 18.82% 19.39% 22.79% 23.08% 21.51% 22.55% -
Total Cost 1,092,785 4,247,224 3,148,072 2,108,849 1,089,851 4,258,549 3,248,091 -51.59%
-
Net Worth 844,199 708,189 809,025 691,775 963,795 776,194 719,914 11.19%
Dividend
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Div - 609,700 304,850 152,425 - 551,075 140,700 -
Div Payout % - 103.21% 62.09% 48.89% - 100.13% 31.12% -
Equity
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Net Worth 844,199 708,189 809,025 691,775 963,795 776,194 719,914 11.19%
NOSH 234,500 234,500 234,500 234,500 234,500 234,500 234,500 0.00%
Ratio Analysis
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
NP Margin 16.80% 12.21% 13.49% 12.88% 14.70% 11.45% 12.22% -
ROE 26.14% 83.41% 60.68% 45.07% 19.49% 70.91% 62.80% -
Per Share
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
RPS 560.11 2,063.09 1,551.82 1,032.25 544.87 2,050.72 1,577.90 -49.83%
EPS 94.11 251.91 209.36 132.96 80.12 234.71 192.78 -37.97%
DPS 0.00 260.00 130.00 65.00 0.00 235.00 60.00 -
NAPS 3.60 3.02 3.45 2.95 4.11 3.31 3.07 11.19%
Adjusted Per Share Value based on latest NOSH - 234,500
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
RPS 560.11 2,063.09 1,551.82 1,032.25 544.87 2,050.72 1,577.90 -49.83%
EPS 94.11 251.91 209.36 132.96 80.12 234.71 192.78 -37.97%
DPS 0.00 260.00 130.00 65.00 0.00 235.00 60.00 -
NAPS 3.60 3.02 3.45 2.95 4.11 3.31 3.07 11.19%
Price Multiplier on Financial Quarter End Date
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Date 31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 -
Price 76.90 73.40 72.10 71.50 73.70 68.50 66.40 -
P/RPS 13.73 3.56 4.65 6.93 13.53 3.34 4.21 119.75%
P/EPS 81.72 29.14 34.44 53.78 91.99 29.19 34.44 77.80%
EY 1.22 3.43 2.90 1.86 1.09 3.43 2.90 -43.82%
DY 0.00 3.54 1.80 0.91 0.00 3.43 0.90 -
P/NAPS 21.36 24.30 20.90 24.24 17.93 20.69 21.63 -0.83%
Price Multiplier on Announcement Date
31/03/16 31/12/15 30/09/15 30/06/15 31/03/15 31/12/14 30/09/14 CAGR
Date 26/04/16 25/02/16 22/10/15 12/08/15 20/04/15 23/02/15 27/10/14 -
Price 75.00 74.56 72.00 71.92 74.48 73.80 68.00 -
P/RPS 13.39 3.61 4.64 6.97 13.67 3.60 4.31 112.76%
P/EPS 79.70 29.60 34.39 54.09 92.96 31.44 35.27 72.11%
EY 1.25 3.38 2.91 1.85 1.08 3.18 2.84 -42.10%
DY 0.00 3.49 1.81 0.90 0.00 3.18 0.88 -
P/NAPS 20.83 24.69 20.87 24.38 18.12 22.30 22.15 -4.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment